Study of cyclosporine and eltrombopag for new bone marrow aplasia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial compares a standard treatment (cyclosporine plus eltrombopag) for adults with newly diagnosed bone marrow aplasia. It aims to see how well this combination works in people who are generally active and have healthy organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be over 18 years old
- Your bone marrow failure must be newly diagnosed
- You should be able to take care of yourself (ECOG score 0-2)
- You must be starting treatment with cyclosporine (CSA) and eltrombopag (Revolade)
- Your heart, liver, and kidneys must be working normally
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment to help restore blood cell production in people with aplastic anemia whose bone marrow isn't working well after a stem cell transplant or other therapies. The goal is to improve blood counts and reduce the need for transfusions or support medications.
This Phase 2 study tests whether starting two oral medicines early—cyclosporine and eltrombopag—can improve severe aplastic anemia in people who have not had prior treatment for it. It may help your blood counts recover without needing stronger or earlier treatments.
This trial tests a lower dose of the chemotherapy drug cyclophosphamide combined with standard immune-suppressing medicines for people with newly diagnosed severe aplastic anemia. The goal is to see if this approach works as well as the usual treatment but with fewer side effects.
This study tests a medicine called avatrombopag for people with aplastic anemia whose blood counts have not improved with standard treatments. Avatrombopag is designed to help the body produce more platelets, which may reduce the risk of bleeding.
This trial tests if sirolimus (an immune-suppressing drug) works better than current treatments for aplastic anemia patients who did not improve or had side effects from cyclosporin. It aims to find a new option to help your body make more blood cells.
This trial tests a new drug called enarodustat combined with an existing immune-suppressing medicine (CsA) to treat aplastic anemia—a rare blood disorder where your bone marrow doesn't make enough blood cells. The goal is to help your body produce more red blood cells without needing a bone marrow transplant.
Hear when a new Aplastic Anemia Idiopathic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.